Illumina (NASDAQ:ILMN) (NASDAQ: ILMN) is a leading provider of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company develops, manufactures and markets next-generation sequencing (NGS) and microarray platforms, consumables and software tools that enable researchers, clinicians and agricultural customers to unlock insights from genomic data. Its product portfolio spans high-throughput sequencing instruments such as NovaSeq, mid-range systems like NextSeq and benchtop devices including MiSeq and iSeq, along with corresponding library preparation kits and reagents.
Illumina’s technologies support a broad array of applications, including whole-genome sequencing, targeted resequencing, transcriptome analysis, epigenetic profiling and genotyping. These solutions are used in academic research, pharmaceutical and biotechnology development, consumer genomics, reproductive health and agrigenomics. The company also offers bioinformatics software and data interpretation services to help customers manage and analyze complex datasets, accelerating discoveries in disease biology, personalized medicine and biomarker development.
Founded in 1998 and headquartered in San Diego, California, Illumina serves a global customer base with regional offices, research and manufacturing sites across North America, Europe, Asia-Pacific and Latin America. Its instruments and consumables are distributed worldwide, supported by a network of application specialists and service engineers. Illumina’s leadership team brings together expertise in genomics, engineering and commercial operations, guiding the company’s strategic focus on expanding access to high-quality genomic data and fostering collaborations across the life sciences community.
